Effectiveness and Safety of Autologous Virus-Specific T-Cell Therapy for Persistent COVID-19 in People With Immunocompromise: A Clinical Trial Study
Year: 2025
Type: article
Study design: Clinical Trial
Abstract: In this prospective study (N = 12), autologous virus-specific T cells (auto-VSTs) were successfully manufactured in 10 patients (83.3%). Three received VSTs, achieving viral clearance and symptom resolution without severe adverse events. Auto-VST therapy appears feasible and effective for managing persistent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection; however, manufacturing and timing challenges remain.
Source: Clinical Infectious Diseases
DOI: 10.1093/cid/ciaf302
Institution: Catholic University of Korea
Language: English
Subfield: Infectious Diseases
Field: Medicine
Domain: Health Sciences
Open Access status: hybrid
Estimated APC paid: $4,763
OpenAlex ID: W4411171040